PENTAM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pentam, and what generic alternatives are available?
Pentam is a drug marketed by Fresenius Kabi Usa, Seton Pharms, X-gen Pharms Inc, Avet Lifesciences, Baxter Hlthcare, Hospira, Watson Labs, and Xgen Pharms. and is included in nine NDAs.
The generic ingredient in PENTAM is pentamidine isethionate. There are fourteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the pentamidine isethionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pentam
A generic version of PENTAM was approved as pentamidine isethionate by SETON PHARMS on September 28th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PENTAM?
- What are the global sales for PENTAM?
- What is Average Wholesale Price for PENTAM?
Summary for PENTAM
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 9 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 104 |
Clinical Trials: | 1 |
Patent Applications: | 1,629 |
Drug Prices: | Drug price information for PENTAM |
DailyMed Link: | PENTAM at DailyMed |
Recent Clinical Trials for PENTAM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Illinois at Chicago |
Pharmacology for PENTAM
Drug Class | Antiprotozoal |